UOC
KALV

UBS O'Connor’s KalVista Pharmaceuticals KALV Stock Holding History

UBS O'Connor’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-79,460
Closed -$898K – 379
2025
Q2 		$898K Sell
79,460
-90,232
-53% -$1.1M 0.02% 235
2025
Q1 		$1.96M Sell
169,692
-3,001
-2% -$30.6K 0.05% 126
2024
Q4 		$1.46M Buy
172,693
+37,141
+27% +$385K 0.04% 195
2024
Q3 		$1.57M Buy
135,552
+12,592
+10% +$158K 0.04% 211
2024
Q2 		$1.45M Buy
122,960
+40,960
+50% +$478K 0.04% 240
2024
Q1 		$973K Buy
+82,000
New +$1.09M 0.03% 278

Other funds holding KALV

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS O'Connor's KALV Position: Q3 2025 in Review

UBS O'Connor sold out of KalVista Pharmaceuticals (KALV) in Q3 2025, closing a stake of 79,460 shares — an estimated $898K sold.

UBS O'Connor first reported a position in KALV in Q1 2024 and held it in 6 quarters. The position peaked at $1.96M in Q1 2025. 145 funds tracked by Wall St. Rank hold KALV as of Q3 2025.

  • UBS O'Connor reported no remaining KalVista Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 79,460 KalVista Pharmaceuticals shares in Q3 2025, an estimated $898K.
  • UBS O'Connor first reported a position in KalVista Pharmaceuticals in Q1 2024 and held it in 6 quarters.
  • UBS O'Connor's KalVista Pharmaceuticals position peaked at $1.96M in Q1 2025.
  • 145 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.